Premium
The use of lidocaine as a test of liver function in liver transplantation
Author(s) -
Potter Julia M.,
Oellerich Michael
Publication year - 1996
Publication title -
liver transplantation and surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1074-3022
DOI - 10.1002/lt.500020307
Subject(s) - medicine , liver transplantation , lidocaine , liver function tests , liver function , transplantation , gastroenterology , intensive care medicine , surgery
The hepatic metabolism of lidocaine to monoethylglycinexylidide (MEGX) is the basis of a dynamic test of liver function. To understand its potential value in liver transplantation, the latter has been considered in the following three separate stages: pretransplantation assessment of potential candidates, potential liver donors, and the transplant recipient. In pretransplantation patients, data support its role in assessing risk of morbidity and mortality. In assessment of the liver transplant donor, there are differences concerning apparent usefulness, and these must be resolved. In the liver transplant recipient, serial measurements are useful to measure real‐time hepatic metabolic activity. Low MEGX values reflect the clinical condition of the patient, and the importance of entirely assessing the patient, not just noting the test result, is paramount. This review has considered the role of the MEGX test in liver transplantation. Copyright © 1996 by the American Association for the Study of Liver Diseases.